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LYs and $271.3 billion (B) due to cervical cancer alone over the 
next 20 years. Based on a realistic linear investment model, RT 
yields an additional 9.8M LYs (2.9M in LIC, 4.7M in LMIC, and 2.2M 
in UMIC) over 20 years, a $53.2B net increase in economic 
productivity ($2.6B in LIC, $16.4B in LMIC, and $34.2B in UMIC), 
and a broader societal net gain of $137.5B ($10.3B in LIC, $44.8B 
in LMIC, and $82.4B in UMIC). The additional investment 
necessary for HDR brachytherapy, an essential component of 
curative treatment, was only 5.5% greater than EBRT alone. 
Conclusions: The failure to ensure global availability of EBRT and 
BT to treat cervical cancer would result in enormous human and 
economic consequences over the next two decades. This loss 
would occur before the benefits of primary cancer prevention 
strategies, such as HPV vaccination, are realized. The present 
study demonstrates that a realistic investment strategy over the 
next 20 years may yield a net economic benefit of up to $150B 
USD, and potentially further benefits beyond that point in time. 
These findings support the value of scaling-up of EBRT and BT to 
treat cervical cancer and help to justify their inclusion in 
national cancer control planning. 
12 
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Purpose: To compare emergency department (ED) use between 
patients with cancer and a matched cancer-free cohort of 
individuals and to examine the association between ED use and 
time to death. 
Methods and Materials: Data were from the Manitoba Centre for 
Health Policy Data Repository and included cancer registry, 
hospital discharge abstracts, physician billing claims, ED visits, 
and vital statistics. The cancer cohort included adults (age 18+) 
with selected cancer diagnoses (breast, colorectal, lung and 
prostate) made between 2007 and 2011. Rates of ED utilization 
were compared during three time periods (pre-, peri-, and post-
diagnosis) using generalized estimating equations between 
cancer patients and cancer-free individuals matched 1:1 on age, 
sex, and Charlson comorbidity score. The association between 
ED use and time to death was tested using a multivariable Cox 
proportional hazards regression model. 
Results: A total of 5569 patients with breast (n = 1555), 
colorectal (n = 1327), lung (n = 1437), and prostate (n = 1250) 
cancer were included. When comparing ED utilization between 
cancer cases by site and their matches only lung cancer showed 
a significant increase during the pre-diagnosis period (relative 
rate [RR] 1.38 [95% confidence interval 1.18-1.62], p < 0.0001). 
ED utilization was increased during the peri-diagnosis period for 
breast (RR 1.74 [1.31-2.32], p = 0.0001), colorectal (RR 2.44 
[1.72-3.45], p < 0.0001), lung (RR 4.51 [3.61-5.63], p < 0.0001), 
and prostate (RR 3.10 [2.14-4.47], p < 0.0001) cancer. In the 
post-diagnosis period, ED utilization was increased for breast (RR 
1.45 [1.26-1.67], p < 0.0001), colorectal (RR 1.40 [1.11-1.76, p = 
0.0005), and lung (RR 2.28 [1.94-2.67], p < 0.0001) cancer. ED 
use in the year prior to diagnosis was associated with time to 
death for prostate cancer (hazard ratio [HR] 1.12 [95% CI 1.02-
1.24], p < 0.02) while ED use in the post-diagnosis period was 
associated with time to death for breast (HR 1.27 [1.18-1.37], p 
< 0.0001), colorectal (HR 1.11 [1.04-1.18], p = 0.0012), and lung 
(HR 1.10 [1.06-1.14], p < 0.0001) cancer. 
Conclusions: The pattern of ED utilization varies with cancer site 
and time from diagnosis. All cancer sites were associated with 
increased ED use around the time of diagnosis, while patients 
with breast, colorectal, and lung cancers also showed increased 
ED use in the post-diagnosis period. Additional cancer-related 
urgent care services during the peri- and post-diagnosis periods 
may alleviate the frequency of ED visits among patients with 
cancer. 
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Purpose: Patients with FIGO Stage II endometrial cancer (EC) are 
generally treated surgically, with risk-adapted adjuvant 
radiotherapy (external beam radiotherapy (EBRT) and/or vaginal 
vault brachytherapy (BT) boost) still suboptimally defined. With 
changing surgical practices in nodal assessment and/or 
resection, opportunity exists for selected patients to receive less 
intensive adjuvant therapy, with the goal of lessening treatment-
related morbidity. In this single-institutional review, we explore 
outcomes of Stage II EC patients treated with adjuvant 
“minipelvis” (MP)-EBRT (a field covering at least the surgical 
bed, vaginal vault, and parametria, but not the classical elective 
nodal regions) +/- BT. 
Methods: Women with pathologic Stage II EC receiving post-
operative MP-EBRT from 2000 onwards were reviewed. 
Demographics, disease characteristics, treatment details, 
survival, and recurrence data were collected. Three-year 
relapse-free survival (RFS) and overall survival (OS) were 
calculated from the date of surgery (Kaplan-Meier method). 
Median RFS and OS were compared between those receiving MP-
EBRT+BT and those receiving MP-EBRT alone (log rank test). 
Univariate analysis was performed (binary logistic regression) to 
determine factors associated with relapse. 
Results: n = 42 patients (median age 63 years [36-86]) received 
adjuvant MP-EBRT (2000-2015), with median follow up 27 months 
(2-105). n = 37 (88%) had pelvic lymph node dissection. 
Endometrioid adenocarcinoma was predominant (71%) over other 
histologies. n = 20 had Grade 3 disease, n = 18 had deep (> 50%) 
myometrial invasion (MI), and n = 22 had lymphovascular invasion 
(LVI). n = 10 received adjuvant chemotherapy. MP-EBRT fields 
had conventional inferior and lateral borders and height less than 
12 cm (range 7.8-11.8). Dose fractionation was typically 45 Gy in 
25 fractions (40-52.6 Gy/20-25), and 32 (76%) received 
subsequent HDR BT boost, typically 15 Gy in three fractions (15-
18 Gy/3) prescribed to vaginal surface. Ten patients relapsed 
(one vaginal recurrence, three in pelvis outside the field, six 
distant), four (40%) of those not receiving BT versus 19% of the 
BT group (OR 3.5, 95%CI 0.7-16.9, p = 0.125). Median time to 
relapse was 20 months (10-32). Tumour grade, LVI, and MI were 
not significantly associated with relapse. Three-year RFS and OS 
were 74% and 92% respectively. 
Conclusions: In this small series, early outcomes following 
adjuvant MP-EBRT for Stage II EC align with those reported for 
conventional adjuvant EBRT, suggesting that this is a reasonable 
approach. Only three patients relapsed in the pelvis outside of 
the field. Further characterization of tumour and toxicity 
outcomes can help to better define the population most likely to 
benefit from MP-EBRT, and the value of BT boost in this setting. 
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Purpose: To document the practice of brachytherapy (BT) and 
external beam radiotherapy (EBRT) for management of cervical 
cancer across Ontario, Canada with a population of 13.6 million. 
Methods and Materials: An electronic survey (SurveyMonkey) 
